Skip to content

Arm A:Lisaftoclax+Daunorubicin+Cytarabine

2 trials

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Conditions

Newly diagnosed intermediate-to-high risk acute myeloid leukemiaNewly diagnosed patients with low-risk acute myeloid leukemia